Why the JP Morgan conference is important — but not make-or-break – statnews.com
This is the online version of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.
My advice for JPM week: chill
SAN FRANCISCO — The super-sized gathering of the biopharma universe is important, but it’s not going to make or break the year for biotech. Acquisitions, partnerships, and funding agreements will be hatched during meetings here over the next week. That’s a major reason why thousands of industry people descend on the city and put up with overpriced hotel rooms.
News flash: All of the stuff that makes biotech go vroom also happens during the 51 remaining weeks of the year.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
